{
    "2018-07-11": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Top 5 Biotech Stocks for 2018",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Stocks",
                        "2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie",
                "features": {
                    "keywords": [
                        "Boeing",
                        "Ford",
                        "American Airlines",
                        "JetBlue",
                        "Pfizer",
                        "Comcast",
                        "Alphabet",
                        "Nvidia",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "aerospace",
                        "automotive",
                        "airlines",
                        "pharmaceuticals",
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Ex-Dividend",
                        "Date",
                        "July 12, 2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "AbbVie's stock falls after lymphoma treatment trial data disappoints",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock",
                        "falls",
                        "lymphoma",
                        "treatment",
                        "trial",
                        "data",
                        "disappoints"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Phase 3",
                        "Study",
                        "Ibrutinib",
                        "IMBRUVICA®",
                        "Blood Cancer",
                        "DLBCL"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; Will Trade Ex-Dividend on July 12, 2018",
                "features": {
                    "keywords": [
                        "Ex-Dividend",
                        "Alert",
                        "AbbVie",
                        "Dividend",
                        "Raised",
                        "140%",
                        "Since 2013",
                        "Trade",
                        "July 12, 2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Updates",
                        "Phase 3",
                        "Study",
                        "Ibrutinib",
                        "Blood Cancer",
                        "DLBCL"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}